Top
Summary
All studies
Cases
RCTs
Peer-reviewed
All outcomes

Feedback
 
Analgesics
Antiandrogens
Antihistamines
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Monoclonals
Mpro inhibitors
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors
TMPRSS2 inh.
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
c19early.org COVID-19 treatment researchSA58SA58 (more..)
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta
Thermotherapy Meta
Melatonin Meta
Metformin Meta

Outcomes in COVID-19 SA58 studies

0 0.5 1 1.5+ All studies 67% 3 4,923 Improvement, Studies, Patients Relative Risk Cases 67% 3 4,923 RCTs 81% 1 1,123 Peer-reviewed 79% 2 4,491 Prophylaxis 67% 3 4,923 SA58 for COVID-19 c19early.org May 2025 FavorsSA58 Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Wang 34% 0.66 [0.55-0.80] cases 44/70 343/362 Improvement, RR [CI] Treatment Control Song (SB RCT) 81% 0.19 [0.08-0.48] symp. case 824 (n) 299 (n) Si 78% 0.22 [0.10-0.48] cases 3,368 (all patients) Tau​2 = 0.56, I​2 = 85.4%, p = 0.018 Prophylaxis 67% 0.33 [0.13-0.83] 44/894 343/661 67% lower risk All studies 67% 0.33 [0.13-0.83] 44/894 343/661 67% lower risk 3 SA58 COVID-19 studies c19early.org May 2025 Tau​2 = 0.56, I​2 = 85.4%, p = 0.018 Effect extraction pre-specified(most serious outcome) Favors SA58 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Wang 34% 0.66 [0.55-0.80] cases 44/70 343/362 Improvement, RR [CI] Treatment Control Song (SB RCT) 81% 0.19 [0.08-0.48] symp. case 824 (n) 299 (n) Si 78% 0.22 [0.10-0.48] cases 3,368 (all patients) Tau​2 = 0.56, I​2 = 85.4%, p = 0.018 Prophylaxis 67% 0.33 [0.13-0.83] 44/894 343/661 67% lower risk All studies 67% 0.33 [0.13-0.83] 44/894 343/661 67% lower risk 3 SA58 COVID-19 case results c19early.org May 2025 Tau​2 = 0.56, I​2 = 85.4%, p = 0.018 Favors SA58 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Song (SB RCT) 81% 0.19 [0.08-0.48] symp. case 824 (n) 299 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.00041 Prophylaxis 81% 0.19 [0.08-0.48] 824 (n) 299 (n) 81% lower risk All studies 81% 0.19 [0.08-0.48] 824 (n) 299 (n) 81% lower risk 1 SA58 COVID-19 Randomized Controlled Trial c19early.org May 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.00041 Effect extraction pre-specified(most serious outcome) Favors SA58 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Song (SB RCT) 81% 0.19 [0.08-0.48] symp. case 824 (n) 299 (n) Improvement, RR [CI] Treatment Control Si 78% 0.22 [0.10-0.48] cases 3,368 (all patients) Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Prophylaxis 79% 0.21 [0.12-0.38] 824 (n) 299 (n) 79% lower risk All studies 79% 0.21 [0.12-0.38] 824 (n) 299 (n) 79% lower risk 2 SA58 COVID-19 peer reviewed studies c19early.org May 2025 Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Effect extraction pre-specified(most serious outcome) Favors SA58 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Wang 34% 0.66 [0.55-0.80] cases 44/70 343/362 Improvement, RR [CI] Treatment Control Song (SB RCT) 81% 0.19 [0.08-0.48] symp. case 824 (n) 299 (n) Song (SB RCT) 62% 0.38 [0.23-0.62] cases 824 (n) 299 (n) Si 78% 0.22 [0.10-0.48] cases 3,368 (all patients) SA58 COVID-19 outcomes c19early.org May 2025 Favors SA58 Favors control
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit